Ridgeback received FDA priority review for ansuvimab to treat Ebola and will donate free drug for those in need in Africa during this ongoing Ebola outbreak. https://t.co/dgjsEJ4LXn
MHRA clearance Thursday April 9. 80 people screened for Phase 1 on Good Friday. 1st person to receive EIDD-2801 this morning in the UK. Amazing teamwork. Fastest trial start ever. Go Ridgeback Go. #CureCovid19#Covid19#Ridgebackbio
https://t.co/i0FMOYwOyn
@llborio@EmoryMedicine Thanks Dr. Borio. Ridgeback Biotherapeutics is collaborating with George Painter and will be taking this into human studies in the next few days.
@ScottGottliebMD EIDD-2801 is oral, easy scalable CMC, can be used early in disease at home. Much less expensive manufacturing vs antibodies. Prevents severe disease in animal models of MERS and SARS.
@martinvars Hi Martin, Follow me @WayneRidgeback We have an oral drug for COVID19. FDA cleared us to go into human studies. It prevents severe disease in animals with MERS and SARS. We hope to show the same in humans with COVID19. Happy to see you are well.
Thanks to Tim Sheahan, Mark Denison, Ralph Baric, George Painter, Wendy Painter for all the great research on EIDD-2801. Human trials to start in days. #COVID19#CURECOVID
Ridgeback to start human testing on EIDD-2801 within days. Oral investigational drug. Animal data in MERS and SARS shows early treatment prevents severe illness. We hope to prove the same in people with COVID-19. #COVID19#CURECOVID19
Questions
1)Is there a relationship between severity of COVID-19 in 30-50 year olds and the exposure to RCCVs from kids through household (parents) and professional (MDs and teachers) contact?
2)Would greater prior exposure the RCCVs result in a milder COVID-19 disease course?
8)Prevalence of anti-RCCV antibodies declines with age in older adults
9)Antibodies to the RCCVs, SARS-COV-1 and MERS isolated from human samples can have some cross reactivity to each other
6)Adults with children are more frequently infected with the 4 RCCVs relative to adults without children
7)Teachers and pediatricians are more likely to be infected with the 4 RCCVs
3)Children are less likely to have severe disease with SARS-COV2
4)Younger kids will have had less exposure to RCCVs vs older kids
5)Within childhood age groups the youngest are more likely to have severe disease
Data reported in the medical literature:
1)There are 4 routinely circulating coronaviruses (RCCVs) that cause mild disease
2)Children are more routinely infected vs adults with the 4 RCCVs in published studies of subjects in NYC and China